Investing in a New Model for Ophthalmic Innovation

Webinars

Banner for a conference on ocular surface disease with three speaker bios and photos: Richard L. Lindstrom, Jodhbir S. Mehta, and Ehsan Sadri, MD. Includes gradient purple graphics and EYEXORA logo at bottom left.
  • September 15, 2026

Advancing Sustained, Interventional Office-based Therapies for Ocular Surface Disease

Watch Video
Slide titled 'Subretinal Fibrosis in Retinal Vascular Diseases' with four speaker bios and photos, including Diana V. Do, Arshad Khanani, David Boyer, and Gemmy Cheung; EYEXORA logo visible.
  • September 15, 2026

Subretinal Fibrosis in Retinal Vascular Diseases

Watch Video

News

  • September 15, 2026

NEW YORK AND SINGAPORE, September 15, 2026 – Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced that it will host a key opNEW YORK AND SINGAPORE, September 15, 2026 – Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced that […]

  • September 10, 2026

NEW YORK AND SINGAPORE, September 10, 2026 – Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced that Theresa Heah, MD, MBA, Chief Executive Officer and Vice Chair, will participate in a fireside chat discussion at the Citizens Virtual Private Ophthalmology Summit on Thursday, September 17, 2026 at […]

  • November 5, 2025

SINGAPORE–(BUSINESS WIRE)–Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced the establishment of its co-headquarters in Singapore, marking a major milestone in the company’s global expansion and deepening its commitment to advancing eye health worldwide. Eyexora’s seed financing was led by ClavystBio, a global life sciences investor based […]

  • September 10, 2025

Claiming the title of the first ophthalmology-focused company with a hub-and-spoke business model, Eyexora debuted on Wednesday with seed funding from ClavystBio to build a global portfolio of devices, as well as anterior and posterior segment therapeutics.

  • September 10, 2025

NEW YORK–(BUSINESS WIRE)– Eyexora announced today its launch as the first company founded to accelerate innovation in ophthalmology using a hub-and-spoke model. The company is building a global portfolio starting with collaborations in Singapore and Europe, with its initial assets in-licensed from the Singapore Eye Research Institute (SERI). Eyexora’s seed financing was led by life […]